252 related articles for article (PubMed ID: 23820854)
1. Sclerostin, an osteocytes-derived bone-forming inhibitor.
Włodarski KH; Galus R; Brodzikowska A; Włodarski PK
Pol Orthop Traumatol; 2013 Jul; 78():151-4. PubMed ID: 23820854
[TBL] [Abstract][Full Text] [Related]
2. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
Poole KE; van Bezooijen RL; Loveridge N; Hamersma H; Papapoulos SE; Löwik CW; Reeve J
FASEB J; 2005 Nov; 19(13):1842-4. PubMed ID: 16123173
[TBL] [Abstract][Full Text] [Related]
3. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin.
Robling AG; Niziolek PJ; Baldridge LA; Condon KW; Allen MR; Alam I; Mantila SM; Gluhak-Heinrich J; Bellido TM; Harris SE; Turner CH
J Biol Chem; 2008 Feb; 283(9):5866-75. PubMed ID: 18089564
[TBL] [Abstract][Full Text] [Related]
4. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling.
Lin C; Jiang X; Dai Z; Guo X; Weng T; Wang J; Li Y; Feng G; Gao X; He L
J Bone Miner Res; 2009 Oct; 24(10):1651-61. PubMed ID: 19419300
[TBL] [Abstract][Full Text] [Related]
5. [Anti-sclerostin antibodies].
Okazaki R
Clin Calcium; 2011 Jan; 21(1):94-8. PubMed ID: 21187600
[TBL] [Abstract][Full Text] [Related]
6. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
[TBL] [Abstract][Full Text] [Related]
7. Osteocytes and WNT: the mechanical control of bone formation.
Galli C; Passeri G; Macaluso GM
J Dent Res; 2010 Apr; 89(4):331-43. PubMed ID: 20200416
[TBL] [Abstract][Full Text] [Related]
8. Bone remodeling in the context of cellular and systemic regulation: the role of osteocytes and the nervous system.
Niedźwiedzki T; Filipowska J
J Mol Endocrinol; 2015 Oct; 55(2):R23-36. PubMed ID: 26307562
[TBL] [Abstract][Full Text] [Related]
9. Sclerostin: recent advances and clinical implications.
Honasoge M; Rao AD; Rao SD
Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):437-46. PubMed ID: 25333305
[TBL] [Abstract][Full Text] [Related]
10. Wnt signaling: a win for bone.
Piters E; Boudin E; Van Hul W
Arch Biochem Biophys; 2008 May; 473(2):112-6. PubMed ID: 18364235
[TBL] [Abstract][Full Text] [Related]
11. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.
Tu X; Rhee Y; Condon KW; Bivi N; Allen MR; Dwyer D; Stolina M; Turner CH; Robling AG; Plotkin LI; Bellido T
Bone; 2012 Jan; 50(1):209-17. PubMed ID: 22075208
[TBL] [Abstract][Full Text] [Related]
12. Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
Toscani D; Bolzoni M; Ferretti M; Palumbo C; Giuliani N
Front Immunol; 2018; 9():2467. PubMed ID: 30410490
[TBL] [Abstract][Full Text] [Related]
13. Pigment epithelium derived factor suppresses expression of Sost/Sclerostin by osteocytes: implication for its role in bone matrix mineralization.
Li F; Song N; Tombran-Tink J; Niyibizi C
J Cell Physiol; 2015 Jun; 230(6):1243-9. PubMed ID: 25363869
[TBL] [Abstract][Full Text] [Related]
14. Does osteocytic SOST suppression mediate PTH bone anabolism?
Kramer I; Keller H; Leupin O; Kneissel M
Trends Endocrinol Metab; 2010 Apr; 21(4):237-44. PubMed ID: 20074973
[TBL] [Abstract][Full Text] [Related]
15. [Mechanical stress and Wnt signal].
Sakai A
Clin Calcium; 2013 Jun; 23(6):839-45. PubMed ID: 23719496
[TBL] [Abstract][Full Text] [Related]
16. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells.
Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC
Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355
[TBL] [Abstract][Full Text] [Related]
17. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
Clarke BL
Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
[TBL] [Abstract][Full Text] [Related]
18. An Akt-dependent increase in canonical Wnt signaling and a decrease in sclerostin protein levels are involved in strontium ranelate-induced osteogenic effects in human osteoblasts.
Rybchyn MS; Slater M; Conigrave AD; Mason RS
J Biol Chem; 2011 Jul; 286(27):23771-9. PubMed ID: 21566129
[TBL] [Abstract][Full Text] [Related]
19. Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders.
Pietrzyk B; Smertka M; Chudek J
Adv Clin Exp Med; 2017 Nov; 26(8):1283-1291. PubMed ID: 29264888
[TBL] [Abstract][Full Text] [Related]
20. Simulated resistance training, but not alendronate, increases cortical bone formation and suppresses sclerostin during disuse.
Macias BR; Swift JM; Nilsson MI; Hogan HA; Bouse SD; Bloomfield SA
J Appl Physiol (1985); 2012 Mar; 112(5):918-25. PubMed ID: 22174402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
